David Kirske Sells 8,543 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO David Kirske sold 8,543 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the sale, the chief financial officer directly owned 167,750 shares of the company’s stock, valued at $714,615. The trade was a 4.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $4.13 on Friday. The company has a market cap of $389.54 million, a P/E ratio of -0.91 and a beta of 0.35. X4 Pharmaceuticals, Inc. has a twelve month low of $1.35 and a twelve month high of $4.83. The company’s 50-day moving average price is $4.09 and its 200-day moving average price is $3.93. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The company had revenue of $2.71 million during the quarter, compared to the consensus estimate of $3.20 million. On average, sell-side analysts forecast that X4 Pharmaceuticals, Inc. will post -0.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on XFOR shares. Wall Street Zen upgraded X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Leerink Partners initiated coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target on the stock. Finally, Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.38.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Indivisible Partners purchased a new position in X4 Pharmaceuticals in the fourth quarter worth approximately $40,000. Rhumbline Advisers lifted its stake in shares of X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the last quarter. SummitTX Capital L.P. acquired a new position in shares of X4 Pharmaceuticals in the 1st quarter valued at $46,000. Two Sigma Investments LP acquired a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $47,000. Finally, Squarepoint Ops LLC purchased a new position in shares of X4 Pharmaceuticals during the 4th quarter worth $50,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.